Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab timing before versus after PCI in acute coronary syndrome
ChiCTR2200057508Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evolocumab in acute coronary syndrome (ACS) (3 arms), sponsored by Tangdu Hospital. Primary endpoints: Change in lipid parameters and Major cardiovascular adverse events. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on ChiCTR2200057508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057508.